RANK-Independent Osteoclast Formation and Bone Erosion in Inflammatory Arthritis

Arthritis and Rheumatology

Volumn 68, Issue 12, 2016, Pages 2889-2900

  O'Brien, William ^a   Fissel, Brian M ^a   Maeda, Yukiko ^b   Yan, Jing ^a   Ge, Xianpeng ^a   Gravallese, Ellen M ^b   Aliprantis, Antonios O ^a   Charles, Julia F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN M; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR; ENZYME INHIBITOR; FC RECEPTOR; NFATC1 PROTEIN, MOUSE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TNFRSF11A PROTEIN, MOUSE; TYROBP PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE EROSION; BONE MARROW CELL; BONE MINERALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE DEVELOPMENT; DRUG EFFECTS; EXPERIMENTAL ARTHRITIS; GENETICS; IMMUNOLOGY; IN VITRO STUDY; KNOCKOUT MOUSE; OSTEOLYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE RESORPTION; CELL PROLIFERATION; ENZYME INHIBITORS; HYDROXYUREA; IN VITRO TECHNIQUES; INTERLEUKIN-6; MICE; MICE, KNOCKOUT; NFATC TRANSCRIPTION FACTORS; OSTEOGENESIS; OSTEOPROTEGERIN; RANK LIGAND; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, IGG; RECEPTORS, INTERLEUKIN-6; TUMOR NECROSIS FACTOR-ALPHA; X-RAY MICROTOMOGRAPHY;

EID: 84997674131     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39837     Document Type: Article

References (45)

1. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 2012;8:656–64.
2. Ollier WE, Harrison B, Symmons D. What is the natural history of rheumatoid arthritis? Best Pract Res Clin Rheumatol 2001;15:27–48.
3. Navarro-Compan V, Landewé R, Provan SA, Odegard S, Uhlig T, Kvien TK, et al. Relationship between types of radiographic damage and disability in patients with rheumatoid arthritis in the EURIDISS cohort: a longitudinal study. Rheumatology (Oxford) 2015;54:83–90.
4. Cohen G, Gossec L, Dougados M, Cantagrel A, Goupille P, Daurès JP, et al. Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis 2007;66:358–63.
5. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004;50:36–42.
6. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250–8.
7. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689–99.
8. Jones D, Glimcher LH, Aliprantis AO. Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. J Clin Invest 2011;121:2534–42.
9. Nakashima T, Hayashi M, Takayanagi H. New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab 2012;23:582–90.
10. Humphrey MB, Lanier LL, Nakamura MC. Role of ITAM-containing adapter proteins and their receptors in the immune system and bone. Immunol Rev 2005;208:50–65.
11. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004;428:758–63.
12. Sitara D, Aliprantis AO. Transcriptional regulation of bone and joint remodeling by NFAT. Immunol Rev 2010;233:286–300.
13. Shen J, Shang Q, Tam LS. Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. Transl Res 2015. E-pub ahead of print.
14. Siebert S, Tsoukas A, Robertson J, McInnes I. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev 2015;67:280–309.
15. Danks L, Komatsu N, Guerrini MM, Sawa S, Armaka M, Kollias G, et al. RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. Ann Rheum Dis 2016;75:1187–95.
16. Kim JH, Jin HM, Kim K, Song I, Youn BU, Matsuo K, et al. The mechanism of osteoclast differentiation induced by IL-1. J Immunol 2009;183:1862–70.
17. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481–8.
18. Yamashita Y, Ukai T, Nakamura H, Yoshinaga Y, Kobayashi H, Takamori Y, et al. RANKL pretreatment plays an important role in the differentiation of pit-forming osteoclasts induced by TNF-α on murine bone marrow macrophages. Arch Oral Biol 2015;60:1273–82.
19. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000;275:4858–64.
20. Hemingway F, Taylor R, Knowles HJ, Athanasou NA. RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone 2011;48:938–44.
21. Li S, Miller CH, Giannopoulou E, Hu X, Ivashkiv LB, Zhao B. RBP-J imposes a requirement for ITAM-mediated costimulation of osteoclastogenesis. J Clin Invest 2014;124:5057–73.
22. Kim N, Kadono Y, Takami M, Lee J, Lee SH, Okada F, et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 2005;202:589–95.
23. Kim HR, Kim KW, Kim BM, Jung HG, Cho ML, Lee SH. Reciprocal activation of CD4+ T cells and synovial fibroblasts by stromal cell-derived factor 1 promotes RANKL expression and osteoclastogenesis in rheumatoid arthritis. Arthritis Rheumatol 2014;66:538–48.
24. Yokota K, Sato K, Miyazaki T, Kitaura H, Kayama H, Miyoshi F, et al. Combination of tumor necrosis factor α and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo. Arthritis Rheumatol 2014;66:121–9.
25. hi osteoclast precursors but is essential for mature osteoclast formation in TNFα-mediated inflammatory arthritis. J Bone Miner Res 2004;19:207–13.
26. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58:1299–309.
27. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010. E-pub ahead of print.
28. Aliprantis AO, Ueki Y, Sulyanto R, Park A, Sigrist KS, Sharma SM, et al. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 2008;118:3775–89.
29. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science 1995;269:1427–9.
30. Mócsai A, Humphrey MB, van Ziffle JA, Hu Y, Burghardt A, Spusta SC, et al. The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (FcRγ) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S A 2004;101:6158–63.
31. –/ HCO3– exchange activity is essential for calpain-dependent regulation of the actin cytoskeleton in osteoclasts. Proc Natl Acad Sci U S A 2013;110:2163–8.
32. Charles JF, Hsu LY, Niemi EC, Weiss A, Aliprantis AO, Nakamura MC. Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J Clin Invest 2012;122:4592–605.
33. Okazaki M, Yamada Y, Nishimoto N, Yoshizaki K, Mihara M. Characterization of anti-mouse interleukin-6 receptor antibody. Immunol Lett 2002;84:231–40.
34. Walsh NC, Reinwald S, Manning CA, Condon KW, Iwata K, Burr DB, et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 2009;24:1572–85.
35. Monach PA, Mathis D, Benoist C. The K/BxN arthritis model. Curr Protoc Immunol 2008;Chapter15:Unit 15.22.
36. Nigrovic PA, Malbec O, Lu B, Markiewski MM, Kepley C, Gerard N, et al. C5a receptor enables participation of mast cells in immune complex arthritis independently of Fcγ receptor modulation. Arthritis Rheum 2010;62:3322–33.
37. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005;202:1261–9.
38. Scherzad A, Steber M, Gehrke T, Rak K, Froelich K, Schendzielorz P, et al. Human mesenchymal stem cells enhance cancer cell proliferation via IL-6 secretion and activation of ERK1/2. Int J Oncol 2015;47:391–7.
39. Yu RY, Wang X, Pixley FJ, Yu JJ, Dent AL, Broxmeyer HE, et al. BCL-6 negatively regulates macrophage proliferation by suppressing autocrine IL-6 production. Blood 2005;105:1777–84.
40. Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, et al. Critical roles for interleukin 1 and tumor necrosis factor α in antibody-induced arthritis. J Exp Med 2002;196:77–85.
41. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest 2002;110:1419–27.
42. Otero JE, Dai S, Alhawagri MA, Darwech I, Abu-Amer Y. IKKβ activation is sufficient for RANK-independent osteoclast differentiation and osteolysis. J Bone Miner Res 2010;25:1282–94.
43. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889–901.
44. Upadhyay A, Senyschyn D, Santos L, Gu R, Carroll GJ, Jazayeri JA. K/BxN serum transfer arthritis is delayed and less severe in leukaemia inhibitory factor (LIF)-deficient mice. Clin Exp Immunol 2012;169:71–8.
45. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 2012;13:134.